These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

392 related items for PubMed ID: 14631124

  • 21. Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging.
    Massacesi L, Parigi A, Barilaro A, Repice AM, Pellicanò G, Konze A, Siracusa G, Taiuti R, Amaducci L.
    Arch Neurol; 2005 Dec; 62(12):1843-7. PubMed ID: 16344342
    [Abstract] [Full Text] [Related]

  • 22. Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis.
    Calabrese M, Bernardi V, Atzori M, Mattisi I, Favaretto A, Rinaldi F, Perini P, Gallo P.
    Mult Scler; 2012 Apr; 18(4):418-24. PubMed ID: 21228025
    [Abstract] [Full Text] [Related]

  • 23. Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data.
    Cohen JA, Calabresi PA, Chakraborty S, Edwards KR, Eickenhorst T, Felton WL, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Imrey PB, Ivancic DM, Mandell BF, Perryman JE, Scott TF, Skaramagas TT, Zhang H, ACT Investigators.
    Mult Scler; 2008 Apr; 14(3):370-82. PubMed ID: 18208877
    [Abstract] [Full Text] [Related]

  • 24. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.
    Lugaresi A, Durastanti V, Gasperini C, Lai M, Pozzilli C, Orefice G, Sotgiu S, Pucci E, Ardito B, Millefiorini E, CoSa Study Group.
    Clin Neuropharmacol; 2008 Apr; 31(3):167-72. PubMed ID: 18520983
    [Abstract] [Full Text] [Related]

  • 25. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients.
    Río J, Nos C, Tintoré M, Téllez N, Galán I, Pelayo R, Comabella M, Montalban X.
    Ann Neurol; 2006 Feb; 59(2):344-52. PubMed ID: 16437558
    [Abstract] [Full Text] [Related]

  • 26. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
    Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L, TRANSFORMS Study Group.
    N Engl J Med; 2010 Feb 04; 362(5):402-15. PubMed ID: 20089954
    [Abstract] [Full Text] [Related]

  • 27. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
    Kappos L, Wiendl H, Selmaj K, Arnold DL, Havrdova E, Boyko A, Kaufman M, Rose J, Greenberg S, Sweetser M, Riester K, O'Neill G, Elkins J.
    N Engl J Med; 2015 Oct 08; 373(15):1418-28. PubMed ID: 26444729
    [Abstract] [Full Text] [Related]

  • 28. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
    Zivadinov R, Dwyer MG, Hussein S, Carl E, Kennedy C, Andrews M, Hojnacki D, Heininen-Brown M, Willis L, Cherneva M, Bergsland N, Weinstock-Guttman B.
    Mult Scler; 2012 Aug 08; 18(8):1125-34. PubMed ID: 22194217
    [Abstract] [Full Text] [Related]

  • 29. Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort.
    Kalincik T, Horakova D, Dolezal O, Krasensky J, Vaneckova M, Seidl Z, Havrdova E.
    Clin Neurol Neurosurg; 2012 Sep 08; 114(7):940-6. PubMed ID: 22402204
    [Abstract] [Full Text] [Related]

  • 30. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR, Panitch HS.
    Clin Ther; 2007 Sep 08; 29(9):2031-48. PubMed ID: 18035202
    [Abstract] [Full Text] [Related]

  • 31. Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial.
    Massacesi L, Tramacere I, Amoroso S, Battaglia MA, Benedetti MD, Filippini G, La Mantia L, Repice A, Solari A, Tedeschi G, Milanese C.
    PLoS One; 2014 Sep 08; 9(11):e113371. PubMed ID: 25402490
    [Abstract] [Full Text] [Related]

  • 32. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy.
    Zivadinov R, Locatelli L, Cookfair D, Srinivasaraghavan B, Bertolotto A, Ukmar M, Bratina A, Maggiore C, Bosco A, Grop A, Catalan M, Zorzon M.
    Mult Scler; 2007 May 08; 13(4):490-501. PubMed ID: 17463072
    [Abstract] [Full Text] [Related]

  • 33. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH.
    Ann Neurol; 1996 Mar 08; 39(3):285-94. PubMed ID: 8602746
    [Abstract] [Full Text] [Related]

  • 34. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
    Sorensen PS, Mellgren SI, Svenningsson A, Elovaara I, Frederiksen JL, Beiske AG, Myhr KM, Søgaard LV, Olsen IC, Sandberg-Wollheim M.
    Lancet Neurol; 2009 Jun 08; 8(6):519-29. PubMed ID: 19409854
    [Abstract] [Full Text] [Related]

  • 35. Comparing efficacy and side effects of a weekly intramuscular biogeneric/biosimilar interferon beta-1a with Avonex in relapsing remitting multiple sclerosis: a double blind randomized clinical trial.
    Nafissi S, Azimi A, Amini-Harandi A, Salami S, shahkarami MA, Heshmat R.
    Clin Neurol Neurosurg; 2012 Sep 08; 114(7):986-9. PubMed ID: 22429566
    [Abstract] [Full Text] [Related]

  • 36. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.
    Rose JW, Burns JB, Bjorklund J, Klein J, Watt HE, Carlson NG.
    Neurology; 2007 Aug 21; 69(8):785-9. PubMed ID: 17709711
    [Abstract] [Full Text] [Related]

  • 37. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.
    Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW, SENTINEL Investigators.
    J Neurol Sci; 2010 May 15; 292(1-2):28-35. PubMed ID: 20236661
    [Abstract] [Full Text] [Related]

  • 38. [Interferon-beta 1a in relapsing-remitting multiple sclerosis. First report of a Mexican population].
    León C, Violante A, Arriada N, Santana HR, Corona T.
    Rev Neurol; 2010 May 15; 31(11):1019-22. PubMed ID: 11190865
    [Abstract] [Full Text] [Related]

  • 39. Rationale and design of the prospective and retrospective observational study of Avonex and Rebif (PROOF) for the treatment of relapsing-remitting multiple sclerosis.
    Murray TJ.
    Curr Med Res Opin; 2004 Jan 15; 20(1):25-30. PubMed ID: 14741068
    [Abstract] [Full Text] [Related]

  • 40. Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States.
    Lee S, Baxter DC, Limone B, Roberts MS, Coleman CI.
    J Med Econ; 2012 Jan 15; 15(6):1088-96. PubMed ID: 22583065
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.